Explore the vast range of titles available.

This surveillance report describes the epidemiology and clinical outcomes of carbapenem-resistant Enterobacterales (CRE) infections in Tennessee from 2016 to 2022, analysing 570 cases and 406 isolates. The incidence of CRE infections per 100 000 population showed an upward trend. Enterobacter species were the most common organisms, whereas Klebsiella species were the main carbapenemase-producing CRE (CP-CRE). Klebsiella pneumoniae carbapenemase was the most common mechanism contributing to this resistance. Demographic characteristics of patients with identified isolates demonstrated a median age of 69.5 years. There were no significant differences in CP-CRE infection by sex or race. Patients with CP-CRE were more likely to be hospitalized than those with non-CP-CRE, at 60.9% and 43.9%, respectively. Multivariable analysis indicated that patients with CP-CRE had significantly higher odds of 90-day mortality (odds ratio, 2.22; 95% confidence interval, 1.12–4.42; p < 0.0001) than non-CP-CRE patients. Individuals with a higher Charlson Comorbidity Index score exhibited an increased odds of dying within 30- and 90-day post-specimen collection and had a greater likelihood of requiring intensive care unit admission. This report underscores the need to understand the epidemiology and risk factors linked to CRE infections to improve prevention strategies and patient care.

Background: Candida auris, a multi-drug resistant fungal pathogen, was first detected in Tennessee healthcare facilities in 2022. C. auris can colonize a patient’s skin and cause clinical infection. Patients with clinical infections have high mortality, with a wide range of reported rates between 30 – 72%. Here we compare the risk factors associated with 30-day all-cause mortality among colonized and clinical cases in Tennessee. Method: Clinical and colonization C. auris case data was obtained from the Tennessee State Public Health Laboratory. Cases with only a skin specimen were classified as colonization, while patients with any other sterile or non-sterile collection site were classified as clinical. Mortality data was obtained through the Tennessee Office of Vital Records and matched with C. auris case information. Risk factors for multi-drug resistant organism acquisition were collected using a REDCap survey completed by facility staff. Chi-square tests were used to compare mortality and risk factor differences. All analyses were conducted in SAS Enterprise Guide v8.3. Result: Between 2022 and 2023, 130 out of 418 colonized patients (31.1%) and 33 out of 108 clinical cases (30.1%) died with no significant differences in age. Of the patients that died, 20 (60.6%) with clinical infection and 50 (38.5%) with colonization died within 30 days of specimen collection (p<.05). However, eight patients with clinical infection who died within 30 days of specimen collection were previously colonized. Risk factors associated with C. auris acquisition were available for 55 patients with clinical infection and 120 with colonization. Patients with clinical infection who died within 30 days of specimen collection were more likely to have incontinent urine (p<.05), a draining wound (p<.05), and have a gastric tube placed (p<.05) than those who survived. Patients with colonization who died within 30 days of specimen collection were more likely to have a previous stay in an inpatient rehabilitation facility (p<.01), an ambulatory surgery center (p<.01), and less likely to have a tracheostomy tube placed (p<.05) than those who survived. Conclusion: Patients with clinical C. auris infection are more likely to die within 30 days of specimen collection than patients with colonization in Tennessee. However, risk factors associated with C. auris acquisition varied between patients with clinical infection or colonization and are not consistently associated with higher mortality. Clinical teams should emphasize infection prevention and control practices that reduce the risk of invasive infection in colonized patients in all settings, regardless of perceived risk.

Background: There are numerous ways to measure social markers of health. One reliable method for predicting health outcomes is the social vulnerability index (SVI) which assesses multiple themes, including housing insecurity, socioeconomic status, and minority status. As a part of Multi-site Gram Negative Surveillance Initiative (MuGSI), surveillance of Extended-Spectrum Beta-Lactamase (ESBL)-producing Enterobacterales was conducted in four Tennessee counties (Maury, Marshall, Wayne, and Lewis). This study examines the association between social vulnerability and infection rates for ESBL-producing Enterobacterales within the surveillance area. Method: ESBL incident cases reported from July 2019 to December 2023 were analyzed. Cases were defined as the first isolation of Escherichia coli, Klebsiella pneumoniae, or Klebsiella oxytoca resistant to at least one extended-spectrum cephalosporin (ceftazidime, cefotaxime or ceftriaxone) and non-resistant to all carbapenem antibiotics from urine or normally sterile sites in residents of the surveillance area within a 30-day period. Pearson correlation analysis was conducted to evaluate the association between SVI scores and ESBL infection rates per 1,000 residents at the census tract level, as well as the four SVI ranking variables (socioeconomic status, household characteristics, racial & ethnic minority status, and housing type & transportation). Analysis was conducted using SAS 9.4. Geospatial analysis in ArcGIS Pro v2.9.7 produced a bivariate choropleth map, illustrating the interaction between SVI and ESBL infection rates. Result: From 2019–2023, 2,166 ESBL cases were reported. Cases were 21% male and 79% female, with mean age of 66 years. Incidence rates ranged from 0.19 to 19.5 per 1,000 population. The analysis revealed a significant positive relationship between SVI and tract-level ESBL infection rates. Higher vulnerability scores are associated with higher infection rates, as evidenced by the positive correlation coefficient (ℝ? = 0.38427, ℝ? = 0.0272). Pearson correlation analysis revealed that household type and transportation demonstrated statistically significant positive correlation with ESBL infection rates (ℝ? = 0.431, ℝ? = 0.0121). Conclusion:Information from geocoding surveillance data can be used to identify social groups at increased risk of infections with drug resistant pathogens. In this study, ESBL infection rate is significantly associated with SVI. Among the four themes, only household type & transportation status is found to be significantly associated with ESBL infection rates. Further research is needed to understand the role housing plays in the spread of ESBL infection, especially looking at both urban and rural populations. Using SVI scores as a risk assessment tool, infection preventionists and antibiotic stewards can prioritize high risk areas for intervention.

To describe antimicrobial use in Tennessee from 2017 to 2023. Retrospective analysis of antimicrobial use using data from the National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) Option. Acute care and critical access facilities in Tennessee. From 2017 to 2023, 97 facilities in Tennessee submitted data to the NHSN AU Option. The number of reporting facilities increased from 25 to 95. During this time, the statewide average antimicrobial use significantly rose from 593 days of therapy (DOT)/1000 days present (DP) to 621 DOT/1000 DP ( = .0478). The All-Antibacterial Standardized Antimicrobial Administration Ratio (SAAR) values remained near 1.0, indicating overall use was as predicted. However, the All-Antibacterial SAAR values, particularly in small facilities, revealed that they utilized antibiotic agents more than predicted during the study period. Additionally, the SAAR trends varied by patient care locations, with the oncology unit (ONC) experiencing a significant increase from 0.73 to 1.12 ( -value<.0001). West Tennessee had the highest antimicrobial use rate at 736 DOT per 1000 DP, and an All-Antibacterial SAAR of 1.21. The top antimicrobial agents-vancomycin, ceftriaxone, piperacillin/tazobactam, cefepime, and cefazolin-accounted for 54% of the total antimicrobial use. This statewide analysis of AU and SAAR trends identifies areas where additional antimicrobial stewardship efforts may be targeted to improve antimicrobial use. Facilities of different sizes and geographic locations have unique demographics that can affect antimicrobial use, requiring specialized antimicrobial stewardship techniques.

Background: According to the Centers for Disease Control and Prevention (CDC), carbapenem-resistant Enterobacterales (CRE) are an urgent public health threat. The CDC states the most common or ‘Big Three’ CRE are Escherichia coli, Enterobacter species, and Klebsiella species. States look at the ‘Big Three’ for guidance when setting reportable condition criteria for CRE. Evaluating trends of the non-‘Big Three’ genera is critical to ensure surveillance efforts are focused on priority targets. Thus, CRE genera trends were evaluated to verify the fitness of CRE surveillance reporting recommendations. Method: The Antimicrobial Resistance Laboratory Network (ARLN) Southeast region (SER) includes Alabama, Florida, Georgia, Louisiana, Mississippi, Tennessee, and Puerto Rico. All CRE is reportable in Tennessee (TN) and isolate submission is required to ARLN. Other jurisdictions submit CRE to the TN regional lab. Submitted CRE cases to ARLN from 2018 – 2023 were analyzed. CRE cases were defined as an Enterobacterales organism resistant to one or more carbapenem, excluding imipenem for Proteus sp., Providencia sp., or Morganella sp. due to intrinsic resistance. Data was cleaned in SAS v9.4 to provide descriptive CRE statistics. Result: The top three genera for TN fluctuate between Enterobacter sp., Klebsiella sp., Proteus sp., and Escherichia sp. In 2022, Proteus sp. (n=132) had twice the incidence of Escherichia sp. (n=65) in TN. There was an overall increasing trend of Proteus sp. from 2018 – 2023. The largest increase of Proteus sp. in TN was seen between 2018 (n=23) and 2021 (n=183). However, the prevalence sharply decreased between 2021 (n=183) and 2023 (n=12). Proteus sp. was 17% (n=627) of all CRE cases (n=3625) in TN from 2018 – 2023, while the “Big Three” was 72% (n=2628). In contrast, Proteus sp. was only 3% (n=35) of all CRE cases (n=1400) in the SER excluding TN from 2018 – 2023, compared to 89% (n=1250) for the “Big Three”. Conclusion: CRE surveillance identified an increased overall prevalence of Proteus sp. in TN between 2018 and 2022 despite not being included in the ‘Big Three’. While there was a large increase of Proteus sp. observed in 2021, the increase was limited to TN, and the subsequent decline suggests this is an outlier. Jurisdictions outside of TN often only submit Carbapenemase-producing CRE to ARLN as not all jurisdictions have CRE as a reportable condition. Results of this analysis suggest the SER should continue to monitor CRE and Proteus sp. to note if there is an increasing overall trend to better inform isolate submission strategies.

Background: Carbapenem-resistant Enterobacterales (CRE) have become an increasing public health challenge in the United States over the past two decades. Carbapenemase-producing CREs (CP-CREs) significantly contribute to the spread of antimicrobial-resistant pathogens in healthcare settings. Tennessee has been conducting surveillance of CRE since 2011. As part of the Emerging Infections Program (EIP), the state has participated in population-based surveillance in Davidson and seven surrounding counties, collaborating with the Centers for Disease Control and Prevention (CDC) since 2014. Methods: The data collected through the Muti-site Gram-negative Surveillance Initiative (MuGSI) project, a collaboration between Tennessee and CDC as part of EIP, was used for this study. The analysis was performed on a subset of CRE isolates tested for carbapenemase production (CP) among all incident CRE cases collected from 2016 to 2022. Incident CRE cases are defined as the identification of carbapenem-resistant E. coli, Enterobacter cloacae complex, and Klebsiella species (K. aerogenes, K. oxytoca, K. pneumoniae, and K. variicola) from urine or normally sterile specimens (e.g., blood) from the residents of the surveillance area in a 30-day period. The mortality data was obtained from the Tennessee Vital Registry and merged with the surveillance data. Cox regression analysis was performed to evaluate if there is a difference in the 90-day survival rate based on the CP status of the pathogen, gender, age group, and the Charlson comorbidity index (CCI) score. Data analysis was done using SAS version 9.4. Results: There were 570 CRE cases reported during the study period (2016-2022). Of these, 406 were tested for carbapenemase production and 87 (21.4%) were positive for CP. There were 269 (66.3%) females and 137 (33.7%) males. Patients with higher Charlson comorbidity index score (> = 5) have significantly higher hazard ratios compared to those with low scores (HR 4.17; p-value) Conclusion: This study indicates that patients infected with CP-CRE, females, and those with high Charlson comorbidity index score have a significantly higher probability of dying within 90 days. These factors are worth considering when conducting a risk assessment of patients infected with drug-resistant gram-negative bacilli. The significantly increased risk of death among patients infected with CP-CRE highlights the need for timely carbapenemase testing and use of the test result for appropriate antimicrobial therapy and infection prevention.

Background: Identification and timely reporting of multi-drug resistant organisms (MDROs) drives efficacy of infection prevention efforts. Data on MDRO reporting timeliness and inter-facility variability are limited. Facility-dependent variability in MDRO reporting across Tennessee was examined to identify opportunities for MDRO surveillance improvement. Methods: Data for reported Tennessee MDROs including carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and Candida auris, were obtained from the southeast regional Antibiotic Resistance Laboratory Network (ARLN) from 2018-2022, excluding screening and colonization specimens. Variance in days accrued from specimen collection to ARLN receipt was analyzed using one-way analysis of variance (ANOVA) with Tukey’s test (SAS 9.4). Facilities were categorized as fast (1-10 days), slow (11-20 days), or delayed (21-100 days) reporters. Results: There were 9,569 MDRO isolates reported. CRPA was reported faster than other MDROs (p < 0.001), while specimens from West Tennessee compared to other regions (p < 0.001) (Figure) and blood cultures compared to other specimens were reported more slowly (p < 0.001) (Table). There was no difference in reporting times for facilities using on-site microbiology laboratories versus reference laboratories (P = 0.062). Conclusion: MDRO reporting times varied across Tennessee by region, specimen, and organism. Future work to elucidate drivers of variability will consist of surveys and focused interviews with laboratory personnel to identify shared and unique barriers and opportunities for improvement.

Background: Antimicrobial resistance is a growing problem in Candida spp., leading to treatment challenges and increased morbidity and mortality. The World Health Organization (WHO) fungal priority pathogens list classifies C. glabrata, C. tropicalis, and C. parapsilosis as high priority and leading causes of candidemia with high fluconazole resistance. In the US, these organisms are the most frequently isolated non-albicans Candida species. In 2016, the Antibiotic Resistance Laboratory Network (ARLN) was created to monitor resistance threats, including in Candida spp. This study describes the proportion of resistance in C. glabrata, C. parapsilosis, and C. tropicalis isolates sent to the Southeast ARLN from 2017 to 2023. Methods: This study evaluated C. glabrata, C. parapsilosis, and C. tropicalis submitted to the Southeast ARLN from Alabama, Florida, Georgia, Louisiana, Mississippi, and Tennessee from February 2017- September 2023. Species identification was confirmed by Bruker Biotyper matrix assisted laser desorption-ionization time of flight (MALDI-TOF). Antifungal susceptibility testing (AFST) was performed using TREK frozen broth microdilution panels. Minimum inhibitory concentration values from the clinical instrument were used to determine susceptibility based on Clinical and Laboratory Standards Institute (CLSI) standard interpretations from the 2020 CLSI M60 guidelines. Data were extracted from the laboratory information management system. Analyses were conducted using SAS v9.4. Results: AFST testing was performed on 660 C. glabrata, 500 C. parapsilosis, and 233 C. tropicalis isolates from within the Southeast region. The predominant specimen sources by species were blood 25.30% C. glabrata; other/not specified 27.80% C. parapsilosis; and lower respiratory 36.91% C. tropicalis. Resistance to fluconazole is as follows: C. glabrata, 12.88%; C. parapsilosis, 3.41%; C. tropicalis, 36.64%. Resistance to voriconazole is as follows: C. parapsilosis, 1.00%; C. tropicalis 30.04%. Resistance to at least one echinocandin (Anidulafungin, Capsofungin, Micafungin) is as follows: C. glabrata, 1.67%; C. parapsilosis, 0.60%; C. tropicalis, 0.43%. Overall, there was a decreasing trend in resistance to fluconazole, and voriconazole in all three species between 2017 and 2023. Conclusions: Antifungal resistance in non-albicans Candida species represents an emerging public health threat, however, within the Southeast region, ARLN data has shown a decreasing trend of azole resistance. This may be due in part to changes in reporting requirements and submission criteria from within the region. Nevertheless, C. tropicalis showed high resistance to azoles within the Southeast region. These Candida species should be monitored to inform clinical decision making and identify resistance patterns in other US regions due to their increase in resistance worldwide.